Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539602 | 0.85 | CA1 (0.47) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL1934604 | 0.85 | CA1 (0.43) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL6706765 | 0.84 | KMT2A (0.52) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL135438 | 0.84 | CA1 (0.44) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL16253852 | 0.82 | KMT2A (0.48) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL29178041 | 0.79 | CA1 (0.39) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL5634656 | 0.79 | CA1 (0.44) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL19198322 | 0.78 | ALB (0.34) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL3490351 | 0.77 | EPHX2 (0.36) | KMT2ACA1CA2EPHX2FABP5 | |
| SCHEMBL26964307 | 0.76 | ALDH1A1 (0.33) | KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889826-B2 | Peptide antibiotics and methods for making same | BIOSOURCE PHARM, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2332965-A1 | Peptide antibiotics and methods for making same | BioSource Pharm, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | BIOSOURCE PHARM, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | VIP, PREP, PEPD | KMT2A 4147/4885CA1 4586/4885CA2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.